Hangzhou Adcoris Biopharmacy Co., Ltd

This early-phase study tests a new drug called ACR246 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 77 adults aged 18 to 75 will take part.